This is a working overview of GHRH analog, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-10-21 and is reviewed periodically as new material appears.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | Built on a 29 residue sequence |
| Primary target | GHRH receptor (GHRHR) | Class B G protein coupled receptor |
| Unconjugated half life | Minutes | Limited by protease degradation |
| Key modification | Four residue substitutions | Positions 2, 8, 15 and 27 |
| Common synonym | Modified GRF(1-29) | Usually denotes the form without DAC |
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
Morgan State began playing football in 1898, 31 years after the school was founded. The Bears have won three MEAC Championships (1976, 1979 and 2014). Their last Division I-AA/FCS playoffs appearance was in 2014. Fifty-three former Morgan players have gone on to play professional football. Former Morgan Bears Len Ford, Leroy Kelly, Willie Lanier and Rosey Brown are members of the Pro Football Hall of Fame in Canton, Ohio.
== Thermal ionization mass spectrometry == Several of the isotope systems involved in radiometric dating depend on IRMS using thermal ionization of a solid sample loaded into the source of the mass spectrometer (hence thermal ionization mass spectrometry, TIMS). These methods include rubidium–strontium dating, uranium–lead dating, lead–lead dating, potassium-calcium dating, and samarium–neodymium dating. When these isotope ratios are measured by TIMS, mass-dependent fractionation occurs as species are emitted by the hot filament. Fractionation occurs due to the excitation of the sample and therefore must be corrected for accurate measurement of the isotope ratio. There are several advantages of the TIMS method. It has a simple design, is less expensive than other mass spectrometers, and produces stable ion emissions. It requires a stable power supply, and is suitable for species with a low ionization potential, such as strontium (Sr), and lead (Pb). The disadvantages of this method stem from the maximum temperature achieved in thermal ionization. The hot filament reaches a temperature of less than 2500°C, leading to the inability to create atomic ions of species with a high ionization potential, such as osmium (Os), and tungsten (Hf-W). Though the TIMS method can create molecular ions instead in this case, species with high ionization potential can be analyzed more effectively with MC-ICP-MS.
=== Elastocaloric refrigeration === Another potential solid-state refrigeration technique and a relatively new area of study comes from a special property of super elastic materials. These materials undergo a temperature change when experiencing an applied mechanical stress (called the elastocaloric effect). Since super elastic materials deform reversibly at high strains, the material experiences a flattened elastic region in its stress-strain curve caused by a resulting phase transformation from an austenitic to a martensitic crystal phase. When a super elastic material experiences a stress in the austenitic phase, it undergoes an exothermic phase transformation to the martensitic phase, which causes the material to heat up. Removing the stress reverses the process, restores the material to its austenitic phase, and absorbs heat from the surroundings cooling down the material. The most appealing part of this research is how potentially energy efficient and environmentally friendly this cooling technology is. The different materials used, commonly shape-memory alloys, provide a non-toxic source of emission free refrigeration. The most commonly studied materials studied are shape-memory alloys, like nitinol and Cu-Zn-Al. Nitinol is of the more promising alloys with output heat at about 66 J/cm3 and a temperature change of about 16–20 K. Due to the difficulty in manufacturing some of the shape memory alloys, alternative materials like natural rubber have been studied.
Sources: en.wikipedia.org
=== Vascular protective effects === 1-MNA exerts beneficial effects on blood vessels through its action on the vascular endothelium. It improves the bioavailability of nitric oxide (NO), which is crucial for vasodilation, and regulates the activity of endothelial nitric oxide synthase (eNOS), the enzyme responsible for NO synthesis. These effects have been demonstrated in both in vivo and in vitro studies. Oral administration of 1-MNA has been shown to increase the diameter of the brachial artery (as measured by flow-mediated dilation, FMD) and stimulate NO release from human endothelial cells in both healthy individuals and those with hypercholesterolemia increased. Additionally, in cases of vascular dysfunction (e.g., hypertriglyceridemia or diabetes), 1-MNA restored normal NO-dependent vasodilation. By increasing NO bioavailability, 1-MNA may counteract endothelial dysfunction, support endothelial regeneration, and improve vascular function, particularly in the context of cardiovascular risk.
Tropoelastin is a protein, of size 72kDa, that comes together via cross-links to form elastin in the extracellular matrix of the cell. The cross-link formation process is mediated by lysyl oxidase. One of the major reasons that elastin can withstand high levels of stress in the body without experiencing any physical deformation is that the underlying tropoelastin contains domains that are highly hydrophobic. These hydrophobic domains, consisting overwhelmingly of alanine, proline, glycine, and valine, tend towards instability and disorderliness, ensuring that the elastin does not lock into any specific confirmation. Thus, ELPs consisting of the Val-Pro-Gly-X-Gly monomeric units, which bear resemblance to the repetitive tropoelastin hydrophobic domains, are highly disordered below their Tt. Even above their Tt in their aggregated state, ELPs are only partially ordered. This is due to the fact that the proline and glycine amino acids are present in high amounts in the ELP. Glycine, due to the lack of a bulky side chain, enables the biopolymer to be flexible and proline prevents the formation of stable hydrogen bonds in the ELP backbone. Certain segments of the ELP may be able to form instantaneous type II β turns, but these turns are not long-lasting and do not resemble true β sheets, when the NMR chemical shifts are compared.
=== Limitations of non-invasive electrical and magnetic methods === Brain tissue stimulation using non-invasive electrical and magnetic methods raises several concerns, including the following: The first issue is the uncertain dose for healthy stimulation. While neurophysiology lacks knowledge about the nature of such a treatment of nervous diseases at the cellular level, non-invasive electrical and magnetic therapies involve excessive exposure of the brain to an intense field, which is several times and even orders of magnitude higher than natural electromagnetic fields in the brain. Another significant challenge of non-invasive electrical and magnetic methods is to localize the effect of stimulation on specific neuronal networks that need to be treated. We still need to gain knowledge about mental processes at the cellular level. Neuronal correlates of cognitive functions are still intriguing questions for contemporary research. Non-invasive electrical and magnetic brain tissue stimulation targets a large area of poorly characterized tissue. Therefore, it is unclear whether electrical and magnetic fields reach only the neuronal networks of the brain that need treatment. Again, these methods involve excessive exposure to intense electrical and magnetic fields several times and even orders of magnitude higher than natural ones in the brain. However, non-invasive electrical and magnetic brain tissue methods cannot target only the neuronal networks that need to be treated. The undefined radiation target can destroy healthy cells during therapy.
Sources: en.wikipedia.org
According to the Chinese chronicles of the Jin dynasty (265-316 CE), there were already a thousand Buddhist stupas and temples in Kucha by the 3rd century CE. The earliest painted caves at Kizil are thought to be Cave of the Hippocampi (Cave 118) and Treasure Caves C and B (Caves 83 and 84 respectively). Cave 118, possibly the earliest of the three, is located deep inside the central valley. Cave 83 and 84 are located at the entrance of the same valley. These caves have simple architectural structures, together with paintings in a clear style, reflecting Indian influences. Noble or wealthy Tocharian donors from Kucha, wearing tunics, sometimes appear kneeling at the side of devotional paintings.
== Critical reception == Gordon Freeman quickly became and then remained one of the most popular video game characters ever. In 2008, The Age ranked him as the 16th-best Xbox character of all time, adding that "no one has done more for the reputations and street cred of theoretical physicists than Valve." In 2009, GameDaily listed the "strong and silent type" in their top 25 video game archetypes, using Gordon Freeman as an example. In 2010, Empire ranked him as the number one Greatest Video Game Character, commenting that "the character is the quintessential geek fantasy" who "has become a gaming icon, synonymous with the apotheosis of first-person action." He was also ranked 14th on UGO.com's list of top 100 heroes in all media, with a comment that "an MIT graduate, donning black-framed glasses and a goatee, he's not the guy you'd picture decimating the alien threat." In 2012, GamesRadar ranked him as the sixth "most memorable, influential, and badass" protagonist in games, adding: "It's how the characters of the Half-Life universe treat Gordon Freeman, not the way he treats them, that shape such a compelling character." In 2013, Complex ranked him as the 45th "most badass" video game character of all time. In 1998, readers of GameSpot ranked him as the fifth-best Hero of gaming. In 2009, a public poll on GameSpot resulted in him being voted the All Time Greatest Video Game Hero. He was also voted as the eighth-best video game character of all time in the Guinness World Records Gamer's Edition 2011.
== Furin == One of the most well-known PPCs is furin. Furin is a serine endoprotease which cleaves protein precursors carboxyterminal of basic residues in motifs such as Arg–X–X–Arg and Lys/Arg–Arg. Cleavage usually results in activation of the proprotein but can also inactivate or modify the activity. Therefore, it is not surprising that it plays a major role in many physiological processes and pathologies, including cancer. Some of its substrates are: proparathyroid hormone, transforming growth factor beta 1 precursor, proalbumin, pro-beta-secretase, membrane type-1 matrix metalloproteinase, beta subunit of pro-nerve growth factor and von Willebrand factor. A furin-like pro-protein convertase has been implicated in the processing of RGMc (also called hemojuvelin). Both the Ganz and Rotwein groups demonstrated that furin-like proprotein convertases (PPC) are responsible for conversion of 50 kDa HJV to a 40 kDa protein with a truncated COOH-terminus, at a conserved polybasic RNRR site. This suggests a potential mechanism to generate the soluble forms of HJV/hemojuvelin (s-hemojuvelin) found in the blood of rodents and humans.
Sources: en.wikipedia.org
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.
DAC stands for drug affinity complex, a term describing the maleimidopropionic acid linker. This group forms a covalent bond with the cysteine residue on serum albumin after administration. The resulting adduct is what extends the circulating half life from minutes to days.
No. It is entirely synthetic and does not correspond to any known endogenous peptide. The design starts from human growth hormone releasing hormone and introduces deliberate substitutions. Any biological effect comes from mimicking the natural hormone at its receptor.
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.